Výsledky vyhledávání - "J, Vandebroek"

Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial

Autor: F. Verhelst, P. Bertrand, J. Verschuere, S. Marien, L. Roex, Johan Vansteenkiste, A. Verstraete, J. Vandebroek, R. Deman, H. Ulrichts, T. De Beukelaar, Maurits Demedts, J. Bockaert, P. De Muynck, W. Van Kerckhoven

Publikováno v: Lung Cancer. 13:295-303

The efficacy and toxicity of a regimen adding ifosfamide to the more classical cisplatin-vindesine combination was studied in patients with advanced non-small cell lung cancer. Sixty-four good performance patients with inoperable stage III or stage I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab648bc319740eca999d5c16bb49bd3e
https://doi.org/10.1016/0169-5002(95)00502-1

Zobrazit plný text záznamu

Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

Autor: S. Marien, N L Dams, R C Devogelaere, Yves Humblet, J. Vandebroek, Kristiaan Nackaerts, Y. Valcke, P. Weynants, D A Verresen, Johan Vansteenkiste

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 12(9)

Background: The modest improvement in median survival of advanced non-small-cell lung cancer (NSCLC) by cisplatin-based chemotherapy has led to the current opinion that clinical benefit for the patient is at least as important an end-point as objecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc6d1f6c090cdf20b85b9303e750e592
https://pubmed.ncbi.nlm.nih.gov/11697823

Zobrazit plný text záznamu

Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU

Autor: M, De Brabander, J, Vandebroek, H, Wassenaar, J, De Crée, A, Baisier, B, Demoen, R, De Ridder, E, Jagers, V, Roels, O, Vogels

Publikováno v: Anticancer research. 15(5B)

Postoperative 5-FU combined with levamisole increases 5 year survival in colon cancer patients (Duke C) by 30% (1). In order to investigate the potential immunological mechanism, we determined lymphocyte subtypes and markers of immune activation in 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::24113146295849e79a60e891a1090e58
https://pubmed.ncbi.nlm.nih.gov/8572636

Zobrazit plný text záznamu

Phase I trial of erbulozole (R55104)

Autor: S J, Van Belle, W, Distelmans, J, Vandebroek, J, Bruynseels, R, Van Ginckel, G A, Storme

Publikováno v: Anticancer research. 13(6B)

Erbulozole (R55 104) is a water soluble congener of the microtubule inhibitor tubulozole, which has proven to possess anti-invasive, antitumoral and radiosensitizing capacities. A dose-finding study was performed on respectively 9 patients (every thr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cce51fc0a53c95a2efb172034339f47b
https://pubmed.ncbi.nlm.nih.gov/8135472

Zobrazit plný text záznamu

THE EFFECTS OF SHORT-TERM TREATMENT WITH LEVAMISOLE ON CYTOKINES IN VOLUNTEERS AND CANCER-PATIENTS

Autor: J Vandebroek, R Deridder, G Storme, H Verhaegen, Jagers E, Roels, F Aerts, R Decoster, O Vogels, Baisier A, J Decree, R Doolaege, S Vanbelle, W Distelmans, M Debrabander, M Dewaele, B Demoen

Publikováno v: International Journal of Oncology.

In search for clues to the potential immunomodulating mechanism of action of levamisole which might be used as monitoring parameters, we have determined a variety of cytokines in the peripheral blood of volunteers and carcinoma patients before and af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ce09e8abcf8223f218d267d880dee2
https://doi.org/10.3892/ijo.1.3.337

Zobrazit plný text záznamu

Levamisole in the treatment of cancer: anything new? (Review)

Autor: M, De Brabander, J, De Crée, J, Vandebroek, H, Verhaegen, P A, Janssen

Publikováno v: Anticancer research. 12(1)

Recently, levamisole combined with 5-FU was shown definitively to increase the survival of patients after surgery for colon cancer (9, 10). In the light of these findings the experimental and clinical findings with levamisole in the field of oncology

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c7617eac90fdf648f46db74ae206fbef
https://pubmed.ncbi.nlm.nih.gov/1567166

Zobrazit plný text záznamu

Weekly paclitaxel versus weekly docetaxel in elderly and frail patients with metastatic breast carcinoma having failed previous anthracyclines: a randomised phase II study of the Belgian Society of Medical Oncology

Autor: L.Y. Dirix, W. Wynendaele, Robert Paridaens, Benoit Beuselinck, J Kains, H. Wildiers, Didier Verhoeven, J. Vandebroek

Publikováno v: Cancer Research. 69:6115

Abstract #6115 Rationale: Taxanes are considered as standard 2nd-line chemotherapy after anthracyclines in metastatic breast carcinoma (MBC). In one large randomized trial, Jones et al. (JCO 2005;23:5542) reported a mean objective remission rate (RR)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53090176eb1ddae2f6cb6020b9500959
https://doi.org/10.1158/0008-5472.sabcs-6115

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání